Quest Diagnostics Inc.’s DGX fourth-quarter 2025 adjusted earnings per share (EPS) of $2.42 beat the Zacks Consensus Estimate by 2.85%. The metric also exceeded the year-ago adjusted figure by 8.5%.

Sanofi SNY announced that the FDA has granted Breakthrough Therapy designation to Wayrilz (rilzabrutinib), a novel oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of

Stocks hitting their 52-week high and delivering consistent performance offer attractive opportunities to investors while building a portfolio. This is because stocks near that level are perceived

CNA Financial Corporation CNA reported fourth-quarter 2025 core earnings of $1.16 per share, which missed the Zacks Consensus Estimate by 3.3%. The bottom line decreased 7.2% year over year.The

Salesforce, Inc. CRM shares have plunged 16.8% over the past six months, underperforming the broader Zacks Computer and Technology sector’s gain of 10.8%.

The sharp contrast raises a tough question

Kimco Realty Corporation KIM is slated to report fourth-quarter 2025 results on Feb. 12, before the opening bell. The company’s quarterly results are likely to display year-over-year growth in

Incyte Corporation INCY reported fourth-quarter 2025 adjusted earnings of $1.80 per share, which missed the Zacks Consensus Estimate of $1.94, primarily due to higher operating expenses. The company

Tuesday, February 10th, 2026Pre-market indexes are pulling back slightly this morning, following another record close from the blue-chip Dow on Monday. Spirits are generally higher than they were